Novo Nordisk A/S’s weight-loss drug semaglutide, offered because the once-weekly Wegovy shot, was efficient as a day by day tablet in a examine.
Individuals with weight problems or who have been chubby and had one other well being drawback misplaced a median of 15.1% of their physique weight when assigned to take the tablet, in contrast with a 2.4% loss in a gaggle given a placebo, the Danish drugmaker mentioned. Each teams additionally made way of life modifications.
About 85% of the semaglutide group misplaced 5% or extra of their physique weight, in contrast with about 26% on placebo. Gastrointestinal unintended effects have been the commonest.
The outcomes are similar to these of a examine with the injectable type of the drug, mentioned Martin Holst Lange, Novo’s government vice chairman for growth. Sufferers might probably be provided a alternative between a day by day tablet or weekly shot, he mentioned.
Learn Extra: What the Ozempic Obsession Misses About Food and Health
The dramatic success of the brand new class of weight-loss medicine has catapulted Novo to Europe’s second-most beneficial firm, behind luxurious group LVMH. Nevertheless, the corporate has struggled to make sufficient of its new medicine to fulfill demand.
There’s a race occurring to develop a weight-loss tablet that’s as efficient as present injections. Pfizer Inc. published constructive mid-stage trial outcomes from its personal tablet, referred to as danuglipron, in JAMA Community on Monday. The Pfizer examine was smaller than Novo’s late-stage trial and centered on sufferers with kind 2 diabetes.
Novo inventory rose 2.7% in Copenhagen on Monday, however its American depositary receipts declined within the U.S. after the Pfizer publication.
The Novo tablet’s future most likely hinges on overcoming manufacturing constraints, particularly due to the big quantity of the medication that’s wanted for dosing by mouth, based on Peter Welford, a London-based analyst with Jefferies. Gross sales of the oral model of the drug might attain $8 billion a 12 months, he wrote in a notice.
Novo expects to file for regulatory approval for the tablet within the U.S. and E.U. this 12 months. A launch will depend upon portfolio priorities and manufacturing capability, the corporate mentioned.
Extra Should-Reads From TIME
